<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468037</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_00020094</org_study_id>
    <nct_id>NCT02468037</nct_id>
  </id_info>
  <brief_title>Effect of Iron Reduction by Phlebotomy for Type 2 Diabetes</brief_title>
  <official_title>Iron Reduction by Phlebotomy for the Prevention and Treatment of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High tissue iron is a risk factor for diabetes even within the broad normal range of normal&#xD;
      human values. In order to demonstrate the benefits of reducing iron on glucose homeostasis&#xD;
      and to better define the parameters for larger clinical trials, the investigators will&#xD;
      subject individuals with prediabetes (impaired glucose tolerance, IGT) or early type 2&#xD;
      diabetes to phlebotomy in order to reduce serum ferritin concentrations and determine the&#xD;
      effect on glucose homeostasis as revealed by oral and frequently sampled intravenous glucose&#xD;
      tolerance testing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Male and female subjects aged 35-65 will be recruited from the clinic populations at the&#xD;
      Medical Centers of the Universities of Colorado, New Mexico, or Utah who have prediabetes, or&#xD;
      diabetes relatively well-controlled (Hemoglobin A1c [HbA1c] ≤ 8.0%) with a single oral agent.&#xD;
      Diabetes/prediabetes status is verified by oral glucose tolerance testing (OGTT) using&#xD;
      criteria of the American Diabetes Association. Serum ferritin will be determined, and&#xD;
      subjects chosen with values in the upper 50% of the normal range, 110-400 ng/mL for males, or&#xD;
      80-240 for females. Exclusion criteria include: hereditary hemochromatosis; cancer (except&#xD;
      cases currently with no evidence of disease); serum creatinine &gt;1.5; anemia (Hgb &lt; lower&#xD;
      limit of normal); chronic inflammatory conditions (rheumatologic conditions such as&#xD;
      rheumatoid arthritis or giant cell arteritis, or chronic infections such as hepatitis B or C)&#xD;
      that could affect ferritin; erythrocyte sedimentation rate or C-reactive protein&gt;1.5 times&#xD;
      the upper limit of normal (UNL); serum transaminases 2 x UNL; hemophilia, warfarin therapy,&#xD;
      or history of GI bleeding; and current glucocorticoid therapy.&#xD;
&#xD;
      After determination of eligibility, subjects are randomized in a 2:1 ratio for treatment and&#xD;
      controls arms. In the fasted state, blood is drawn for determination of adiponectin and&#xD;
      lipids (HDL, direct LDL, triglycerides). Subjects have the option of participating in a&#xD;
      frequently sampled intravenous glucose tolerance test (FSIVGTT). All subjects receive&#xD;
      counseling to follow a healthy diet and regular exercise. Phlebotomy occurs at the rate of&#xD;
      500 ml (one Unit) of blood per month over the period of 3-6 months. At two-month intervals,&#xD;
      serum ferritin and complete blood counts are determined. When serum ferritin reaches the&#xD;
      lowest quartile of normal (&lt;50 ng/mL for females and &lt;70 ng/mL for males, but no sooner than&#xD;
      3 months or later than 6 months after beginning phlebotomy, metabolic status will be&#xD;
      reassessed by fasting lipids, adiponectin, OGTT, and optionally, FSIVGTT. Controls are&#xD;
      recalled for repeat testing 6-8 months after enrollment.&#xD;
&#xD;
      120 min OGTT and FSIVGTT are performed on separate days after an overnight fast. FSIVGTT data&#xD;
      are analyzed using MINMOD Millennium software. Areas under the glucose curve (AUCglucose) are&#xD;
      calculated using the trapezoidal method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in glucose area under the curve.</measure>
    <time_frame>6 months after initiation of phlebotomy</time_frame>
    <description>As determined by oral glucose tolerance testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in insulin sensitivity</measure>
    <time_frame>6 months after initiation of phlebotomy</time_frame>
    <description>As determined by intravenous glucose tolerance testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in insulin secretory capacity</measure>
    <time_frame>6 months after initiation of phlebotomy</time_frame>
    <description>As determined by intravenous glucose tolerance testing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Phlebotomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receive counseling to follow a healthy diet and regular exercise. Phlebotomy occurs at the rate of 500 ml (one Unit) of blood per month over the period of 3-6 months. At two-month intervals, serum ferritin and complete blood counts are determined. When serum ferritin reaches the lowest quartile of normal (&lt;50 ng/mL for females and &lt;70 ng/mL for males, but no sooner than 3 months or later than 6 months after beginning phlebotomy, subjects will be retested for glucose tolerance as described</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects receive counseling to follow a healthy diet and regular exercise.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phlebotomy</intervention_name>
    <description>Patients donate blood until tissue iron levels are in the lowest quartile of normal.</description>
    <arm_group_label>Phlebotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 35-65&#xD;
&#xD;
          -  Prediabetes, or diabetes relatively well-controlled (Hemoglobin A1c [HbA1c] ≤ 8.0%)&#xD;
             with a single oral agent as defined by oral glucose tolerance testing (OGTT) using&#xD;
             criteria of the American Diabetes Association.&#xD;
&#xD;
          -  Serum ferritin values in the upper 50% of the normal range, 110-400 ng/mL for males,&#xD;
             or 80-240 for females.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hereditary hemochromatosis;&#xD;
&#xD;
          -  cancer (except cases currently with no evidence of disease);&#xD;
&#xD;
          -  serum creatinine &gt;1.5;&#xD;
&#xD;
          -  anemia (Hgb &lt; lower limit of normal);&#xD;
&#xD;
          -  chronic inflammatory conditions (rheumatologic conditions such as rheumatoid arthritis&#xD;
             or giant cell arteritis, or chronic infections such as hepatitis B or C) that could&#xD;
             affect ferritin;&#xD;
&#xD;
          -  erythrocyte sedimentation rate or C-reactive protein&gt;1.5 times the upper limit of&#xD;
             normal (UNL);&#xD;
&#xD;
          -  serum transaminases 2 x UNL;&#xD;
&#xD;
          -  hemophilia,&#xD;
&#xD;
          -  warfarin therapy,&#xD;
&#xD;
          -  history of GI bleeding;&#xD;
&#xD;
          -  current glucocorticoid therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald McClain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>June 5, 2015</last_update_submitted>
  <last_update_submitted_qc>June 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Donald McClain</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>iron</keyword>
  <keyword>diabetes</keyword>
  <keyword>phlebotomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

